← Who reports today · Health Care
How Stryker Corporation (SYK) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · reported 07/30/2026
Stryker Corporation is an American multinational medical technologies corporation based in Portage, Michigan, United States. · Wikipedia
More about the company
The company's products are used for medical surgery and neurotechnology, which include surgical equipment, patient and caregiver safety technologies, endoscopy systems, and patient handling, emergency medical equipment, and intensive care disposable products, as well as neurosurgical, neurovascular and oral and maxillofacial surgery implant products; and orthopedic surgery, which includes implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. Stryker's products are sold in over 75 countries and are used by 150 million patients annually. In 2024, 75% of the company's revenues came from the United States.
Key growth driver: MedSurg & Neurotechnology — the fastest-growing revenue line: $3,625, +10% y/y. · by the Q2 2026 report
How does Stryker make money?
Stryker brought in $6.59 billion of revenue in Q2 2026, up 9.4% year over year. The largest source was MedSurg & Neurotechnology: $3.63 billion, or 55% of the total, followed by Orthopaedics ($2.96B, 45%). Net income for the quarter was $1.28 billion, up 44.3% year over year.
Revenue by source, Q2 2026
- MedSurg & Neurotechnology$3.63B · 55% · +9.7%
- Orthopaedics$2.96B · 45% · +9.1%
Shares of $6.59B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is SYK’s next earnings date?
Thursday, October 29, 2026confirmed · after market close
Stryker Corporation (SYK) is scheduled to report results for the quarter ending Sep 2026 on Oct 29, 2026. Consensus EPS forecast: $3.60 (9 analysts), vs $3.19 in the same quarter last year.
What time does SYK report? Usually after market close: the last 4 results releases reached the SEC at 4:09 pm, 4:07 pm, 4:11 pm, 4:15 pm ET.
Last report: Jul 30, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Revenue
$6,589
+9.4%
Gross profit
$4,498
+17.1%
68.3% margin
Operating income
$1,659
+49.1%
25.2% margin
Net income
$1,276
+44.3%
$3.30 diluted EPS
Verdict: a strong recovery quarter—9.4% sales growth and a 158M tariff-charge reversal drove operating margin up 670bps and net earnings up 44%, though adjusted EPS growth of 18% better reflects underlying momentum post cyber-incident.
6-mo OCF $1,842M (+35% y/y); dividends paid $674M (6mo); narrowed FY26 guidance to 8.3-9.3% organic growth and adjusted EPS of $14.95-$15.10.
Source and notation
* marks non-cash / ≈ estimated. Source: Stryker press release / 10-Q (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
SYK earnings history: past report dates
| Jul 30, 2026 Thu | 4:09 pmafter market close | Jun 30, 2026 | $6.6B+9% y/y | $3.30+44% y/y |
| Apr 30, 2026 Thu | 4:07 pmafter market close | Mar 31, 2026 | $6.0B+3% y/y | $1.93+14% y/y |
| Jan 29, 2026 Thu | 4:11 pmafter market close | Dec 31, 2025 | $7.2B+11% y/y | $2.20+56% y/y |
| Oct 30, 2025 Thu | 4:15 pmafter market close | Sep 30, 2025 | $6.1B+10% y/y | $2.22+3% y/y |
| Jul 31, 2025 Thu | 4:12 pmafter market close | Jun 30, 2025 | $6.0B+11% y/y | $2.29+7% y/y |
| May 1, 2025 Thu | 4:10 pmafter market close | Mar 31, 2025 | $5.9B+12% y/y | $1.69−18% y/y |
| Jan 28, 2025 Tue | 4:07 pmafter market close | Dec 31, 2024 | $6.4B+11% y/y | $1.41−53% y/y |
| Oct 29, 2024 Tue | 4:09 pmafter market close | Sep 30, 2024 | $5.5B+12% y/y | $2.16+20% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Stryker Corporation: 5-year financials
| 2025 | 25,116 | 4,889 | 3,246 | 4,283 | 1,284 |
| 2024 | 22,595 | 3,689 | 2,993 | 3,487 | 1,219 |
| 2023 | 20,498 | 3,888 | 3,165 | 3,136 | 1,139 |
| 2022 | 18,449 | 2,841 | 2,358 | 2,036 | 1,051 |
| 2021 | 17,108 | 2,584 | 1,994 | 2,738 | 950 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
2/2good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Feb 2026Cover of the 2025 10-K: one registered class of common stock — Common Stock, $.10 par value (NYSE: SYK). sec.gov ↗
- Feb 2026Diluted weighted average shares +1.6% over 2020–2025; SBC $243M — 1.0% of $25.1B revenue. data.sec.gov ↗
- Feb 2026Declared dividend: $2.585 (2021) → $2.835 → $3.05 → $3.24 → $3.40 per share (2025). sec.gov ↗
- Feb 202610-K: in 2025 the SEC and DOJ notified the company they had closed their FCPA inquiries; no shareholder disclosure suits. sec.gov ↗
Scoring: 2.0 with no deductions = 2.0 (single share class, diluted shares +1.6% over 5 years, dividend raised every year, no shareholder lawsuits; SEC/DOJ FCPA inquiries closed in 2025)
- Share classes
- 10-K cover: one class — Common Stock $.10 (NYSE: SYK) plus euro-denominated notes.
- Dilution
- Diluted shares +1.6% over 2020–2025; deals (Wright Medical, Inari and others) paid in cash; SBC 1% of revenue.
- Disclosure
- Full reporting, no violations.
- Dividends
- Declared dividend rising: $2.585 (2021) → $3.40 (2025).
- Lawsuits & regulators
- 10-K: product liability (implants) and patent suits; the SEC and DOJ closed their FCPA inquiries in 2025 with no action; the 2013/2018 SEC FCPA cases are not deducted under the methodology; no shareholder lawsuits.
- Related parties
- No material related-party transactions.
How the score works · checked as of Sep 2026
Stryker Corporation (SYK) earnings: FAQ
How does Stryker make money?
Stryker brought in $6.59 billion of revenue in Q2 2026, up 9.4% year over year. The largest source was MedSurg & Neurotechnology: $3.63 billion, or 55% of the total, followed by Orthopaedics ($2.96B, 45%). Net income for the quarter was $1.28 billion, up 44.3% year over year.
When is SYK's next earnings date?
Stryker Corporation (SYK) is scheduled to report on Oct 29, 2026, after market close.
What time does SYK report earnings?
Stryker Corporation is scheduled to report after market close on Oct 29, 2026. Its last results releases were filed after market close, most recently at 4:09 pm ET on Jul 30, 2026.
When did SYK last report earnings?
Stryker Corporation reported Q2 2026 results on Jul 30, 2026.
What is the EPS estimate for SYK's next earnings?
The consensus EPS forecast is $3.60 (9 analysts), vs $3.19 in the same quarter last year.
Where can I find Stryker Corporation's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to SYK's filings; this page breaks the latest report down in a Sankey chart.
What was SYK's net income in Q2 2026?
Stryker Corporation reported net income of $1,276M for Q2 2026 (+44.3% year over year), under US GAAP.
Does Stryker Corporation pay dividends?
Yes. In 2025, Stryker Corporation paid $1,284M in dividends on its common stock, per its 10-K. Earlier years are in the five-year table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 08/25/2026. How we make the breakdowns · Report an error
More reports: TMO · Q2 2026 · UNH · Q2 2026 · VRTX · Q2 2026 · ABBV · Q2 2026 · ABT · Q2 2026 · AMGN · Q2 2026 · BMY · Q2 2026 · CI · Q2 2026 · CVS · Q2 2026 · DHR · Q2 2026 · all reports